Experience with Olan in overdosage is limited.
Symptoms: In the patient taking the largest identified amount, 300 mg, the only symptoms reported were drowsiness and slurred speech. In the limited number of patients who were evaluated in hospitals, including the patient taking 300 mg, there were no observations indicating an adverse change in laboratory analytes or ECG. Vital signs were usually within normal limits following overdoses.
Based on animal data, the predicted symptoms would reflect an exaggeration of the drug's known pharmacological actions. Symptoms may include somnolence, mydriasis, blurred vision, respiratory depression, hypotension and possible extrapyramidal disturbances.
Treatment: There is no specific antidote to Olan; therefore, appropriate supportive measures should be initiated. The possibility of multiple drug involvement should be considered.
In case of acute overdosage, establish and maintain an airway and ensure adequate oxygenation and ventilation. The use of activated charcoal for overdose should be considered because the concomitant administration of activated charcoal was shown to reduce the oral bioavailability of Olan by 50-60%.
Hypotension and circulatory collapse should be treated with appropriate measures eg, IV fluids and/or sympathomimetic agents eg, norepinephrine (do not use epinephrine, dopamine or other sympathomimetic agents with β-agonist activity since β-stimulation may worsen hypotension in the setting of α-blockade induced by olanzapine). Cardiovascular monitoring should be considered to detect possible arrhythmias. Close medical supervision and monitoring should continue until the patient recovers.